As supply chains shift and vendor arrangements evolve in response to tariffs, life sciences companies must adapt to increasingly intricate and intertwined challenges across operational and commercial needs. Manufacturing relocation, technology adoption, and new vendor partnerships require careful oversight of labor, compliance, human rights, and union matters. Protecting…

Following 16 years of negotiations, the Trade and Economic Partnership Agreement (TEPA) between India and the EFTA (European Free Trade Association) States – Switzerland, Iceland, Norway, and Liechtenstein – will enter into force on 1 October 2025. As the first European countries to conclude a free trade agreement…

Amid fluctuating tariffs and complex trade policies, healthcare and life sciences (HLS) companies face mounting operational and legal challenges within their global supply chains. Organizations are taking steps to retool their supply chains in response to threats against stability, but change introduces myriad knock-on implications. In the second article…

The healthcare and life sciences sector is facing new trade winds and a looming threat of increased tariffs. This places additional pressure on a typical life sciences supply chain timeline. We recently launched a four-part article series on supply chains, aimed at exploring the legal and operational complexities…

Following the US administration’s’ extensive new import tariffs, many companies are grappling with increased costs and supply chain uncertainty. What happens when a deal becomes financially unsustainable due to government-imposed trade restrictions? Companies should consider the force majeure and change management clauses in their contracts, and the doctrines…